A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB1020 in Hepatic Insufficiency and Cirrhosis Patients
Latest Information Update: 14 Oct 2020
At a glance
- Drugs SYNB 1020 (Primary)
- Indications Hyperammonaemia; Liver cirrhosis
- Focus Adverse reactions
- Sponsors Synlogic
- 20 Aug 2019 According to a Synlogic media release, detailed results of this study will be presented at a future scientific or medical conference.
- 20 Aug 2019 Status changed from recruiting to discontinued, according to a Synlogic media release.
- 20 Aug 2019 Top-line interim results presented in the Synlogic media release.